Conjugation to 4-aminoquinoline improves the anti-trypanosomal activity of Deferiprone-type iron chelators

Imagem de Miniatura
Arquivos
art_PINTO_Conjugation_to_4_aminoquinoline_improves_the_anti_trypanosomal_2013.PDF (579.39 KB)
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
GEHRKE, Sebastian S.
STEVERDING, Dietmar
PLEBAN, Karin
TEMPONE, Andre G.
HIDER, Robert C.
WAGNER, Gerd K.
Citação
BIOORGANIC & MEDICINAL CHEMISTRY, v.21, n.3, p.805-813, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Iron is an essential growth component in all living organisms and plays a central role in numerous biochemical processes due to its redox potential and high affinity for oxygen. The use of iron chelators has been suggested as a novel therapeutic approach towards parasitic infections, such as malaria, sleeping sickness and leishmaniasis. Known iron chelating agents such as Deferoxamine and the 3-hydroxypyridin-4-one (HPO) Deferiprone possess anti-parasitic activity but suffer from mammalian toxicity, relatively modest potency, and/or poor oral availability. In this study, we have developed novel derivatives of Deferiprone with increased anti-parasitic activity and reduced cytotoxicity against human cell lines. Of particular interest are several new derivatives in which the HPO scaffold has been conjugated, via a linker, to the 4-aminoquinoline ring system present in the known anti-malaria drug Chloroquine. We report the inhibitory activity of these novel analogues against four parasitic protozoa, Trypanosoma brucei, Trypanosoma cruzi, Leishmania infantum and Plasmodium falciparum, and, for direct comparison, against human cells lines. We also present data, which support the hypothesis that iron starvation is the major cause of growth inhibition of these new Deferiprone-Chloroquine conjugates in T. brucei.
Palavras-chave
Iron chelator, Anti-parasitic, Trypanosoma, Hybrid drugs, Deferiprone
URI
https://observatorio.fm.usp.br/handle/OPI/2471
Referências
  1. ATKINSON CT, 1991, AM J TROP MED HYG, V45, P593
  2. Barrett MP, 2011, FUTURE MICROBIOL, V6, P1037, DOI [10.2217/fmb.11.88, 10.2217/FMB.11.88]
  3. Brand S, 2012, J MED CHEM, V55, P140, DOI 10.1021/jm201091t
  4. Breidbach T, 2002, INT J PARASITOL, V32, P473, DOI 10.1016/S0020-7519(01)00310-1
  5. Croft SL, 2011, CLIN MICROBIOL INFEC, V17, P1478, DOI 10.1111/j.1469-0691.2011.03630.x
  6. Davis RA, 2012, J MED CHEM, V55, P5851, DOI 10.1021/jm3002795
  7. DOBBIN PS, 1993, J MED CHEM, V36, P2448, DOI 10.1021/jm00069a002
  8. Fast B, 1999, BIOCHEM J, V342, P691, DOI 10.1042/0264-6021:3420691
  9. Gans P, 1999, ANN CHIM-ROME, V89, P45
  10. Grecco SS, 2010, PARASITOL RES, V106, P1245, DOI 10.1007/s00436-010-1771-8
  11. Guantai EM, 2011, J MED CHEM, V54, P3637, DOI 10.1021/jm200149e
  12. HERSHKO C, 1992, J INORG BIOCHEM, V47, P267, DOI 10.1016/0162-0134(92)84072-U
  13. HERSHKO C, 1991, BLOOD, V77, P637
  14. HERSHKO C, 1988, J EXP MED, V168, P375, DOI 10.1084/jem.168.1.375
  15. Hider RC, 1997, J PHARM PHARMACOL, V49, P59
  16. Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2
  17. Kong XL, 2006, J MED CHEM, V49, P3028, DOI 10.1021/jm050905t
  18. Lescure FX, 2010, LANCET INFECT DIS, V10, P556, DOI 10.1016/S1473-3099(10)70098-0
  19. LYTTON SD, 1994, BLOOD, V84, P910
  20. Martinez A, 2012, J MED CHEM, V55, P3867, DOI 10.1021/jm300070h
  21. Mellor HR, 2003, BIOCHEM J, V374, P307, DOI 10.1042/BJ20030348
  22. Merschjohann Karin, 2006, Kinetoplastid Biol Dis, V5, P3, DOI 10.1186/1475-9292-5-3
  23. Mikus Judith, 2000, Parasitology International, V48, P265, DOI 10.1016/S1383-5769(99)00020-3
  24. Moncayo A, 2009, MEM I OSWALDO CRUZ, V104, P17, DOI 10.1590/S0074-02762009000900005
  25. Perez B, 2012, CHEMMEDCHEM, V7, P1537, DOI 10.1002/cmdc.201200257
  26. Perez BC, 2012, EUR J MED CHEM, V54, P887, DOI 10.1016/j.ejmech.2012.05.022
  27. Pink R, 2005, NAT REV DRUG DISCOV, V4, P727, DOI 10.1038//nrd1824
  28. Reimao JQ, 2010, BIOORGAN MED CHEM, V18, P8044, DOI 10.1016/j.bmc.2010.09.015
  29. Ruiz FAR, 2011, BIOORGAN MED CHEM, V19, P4562, DOI 10.1016/j.bmc.2011.06.025
  30. Sashidhara KV, 2012, BIOORGAN MED CHEM, V20, P2971, DOI 10.1016/j.bmc.2012.03.011
  31. SCOTT MD, 1990, BRIT J HAEMATOL, V75, P598, DOI 10.1111/j.1365-2141.1990.tb07805.x
  32. SILFEN J, 1988, BIOCHEM PHARMACOL, V37, P4269, DOI 10.1016/0006-2952(88)90606-5
  33. SOTERIADOU K, 1995, J ANTIMICROB CHEMOTH, V35, P23, DOI 10.1093/jac/35.1.23
  34. Stec J, 2012, J MED CHEM, V55, P3088, DOI 10.1021/jm2015183
  35. Steverding D, 2005, EXPERT OPIN INV DRUG, V14, P939, DOI 10.1517/13543784.14.8.939
  36. Taylor MC, 2010, PARASITOLOGY, V137, P899, DOI 10.1017/S0031182009991880
  37. Tempone AG, 2009, PARASITOL RES, V105, P499, DOI 10.1007/s00436-009-1427-8
  38. Thuma PE, 1998, AM J TROP MED HYG, V58, P358
  39. Weinberg ED, 1998, REV MED MICROBIOL, V9, P171
  40. Coura J R, 1985, Mem Inst Oswaldo Cruz, V80, P73
  41. World Health Organization, 2010, M WHO EXP COMM CONTR

Coleções
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - ODS/03